Acrixolimab is under clinical development by Y-Biologics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Acrixolimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Acrixolimab overview

Acrixolimab (YBL-006) is under development for the treatment of non-small cell lung cancer,  recurrent head and neck squamous cell carcinoma, non-clear cell RCC (renal cell carcinoma), aSCC (anal squamous cell carcinoma), uterine cervical cancer, cSCC (cutaneous squamous cell carcinoma of the skin), uterine endometrial carcinoma, TMB-H (high tumor mutation burden) tumors, epithelial tumor of the penis (squamous cell carcinoma or adenocarcinoma), neuroendocrine tumor (any origin, pancreatic or non-pancreatic), and nasopharyngeal cancer. It is administered through intravenous route. It acts by targeting programmed cell death protein 1 (PD1) and programmed cell death 1 ligand 1 (PD L1). The drug candidate is a monoclonal antibody developed based on human antibody library (Ymax-ABL), receptor library (Ymax-CEPT) and mammalian transient expression (Ymax-tEXPRESS). 

It was under development for the treatment of melanoma and colorectal cancer.

Y-Biologics overview

Y-Biologics, a R&D company focusing on antibody therapeutics in cancer, autoimmune diseases, and metabolic disease. The company is headquartered in Republic of Korea (South Korea).

For a complete picture of Acrixolimab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.